Hetrombopag: First Approval

<p><b>Declarations</b></p> <p><b><br></b></p><p><b>Funding</b> The preparation of this review was not supported by any external funding.</p> <p><b><br></b></p><p><b>Authorship and Conflict of interest</b> Yahiya Y. Syed is a salaried employee of Adis International Ltd/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.</p> <p> </p> <p><b><br></b></p><p><b>Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability</b> not applicable<b></b></p> <p> </p> <p><br></p><p>Additional information about this Adis Drug Review can be found <a href="https://www.springer.com/gp/adis/products-services/adis-journals-newsletters/adis-drug-reviews">here</a></p> <p> </p> <p><b><br></b></p><p><b>Abstract</b></p> <p>Hetrombopag (Hengqu^®), an oral nonpeptide thrombopoietin receptor agonist, is being developed by Jiangsu Hengrui Pharmaceutical for the treatment of thrombocytopenia and aplastic anaemia. On 16 June 2021 hetrombopag received its first approval in China as a second-line treatment for primary immune thrombocytopenia (ITP) and severe aplastic anaemia (SAA) in adults. The drug is also undergoing phase III development in China for the treatment of chemotherapy-induced thrombocytopenia. This article summarizes the milestones in the development of hetrombopag leading to this first approval for ITP and SAA.</p> <p> </p> <p><br></p><p>© Springer Nature Switzerland AG 2021</p>